Rocket Pharmaceuticals, Inc.
RCKT
$3.60
-$0.04-1.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.62% | -15.16% | 2.10% | 22.25% | 41.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.31% | -16.36% | -8.72% | -0.98% | 3.20% |
| Operating Income | 21.31% | 16.36% | 8.72% | 0.98% | -3.20% |
| Income Before Tax | 18.85% | 13.77% | 6.65% | -1.60% | -3.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.85% | 13.77% | 6.65% | -1.60% | -3.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.85% | 13.77% | 6.65% | -1.60% | -3.49% |
| EBIT | 21.31% | 16.36% | 8.72% | 0.98% | -3.20% |
| EBITDA | 22.16% | 17.56% | 9.87% | 1.78% | -2.34% |
| EPS Basic | 28.56% | 26.48% | 18.39% | 10.36% | 8.40% |
| Normalized Basic EPS | 29.54% | 27.42% | 19.25% | 11.56% | 8.72% |
| EPS Diluted | 28.56% | 26.48% | 18.39% | 10.36% | 8.40% |
| Normalized Diluted EPS | 29.54% | 27.42% | 19.25% | 11.56% | 8.72% |
| Average Basic Shares Outstanding | 12.89% | 17.28% | 14.79% | 13.64% | 13.01% |
| Average Diluted Shares Outstanding | 12.89% | 17.28% | 14.79% | 13.64% | 13.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |